Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35262430/
This study provides insight regarding the comparative efficacy of drugs for which no head-to-head trials exist and suggests that inclisiran, alirocumab, and evolocumab are expected to provide similar clinically meaningful...
Conclusions: This study provides insight regarding the comparative efficacy of drugs for which no head-to-head trials exist and suggests that inclisiran, alirocumab, and evolocumab are expected to provide similar clinically meaningful improvements in low-density lipoprotein cholesterol in patients with hypercholesterolemia on maximally...
Share
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35246337/
doi: 10.1016/j.clinthera.2021.12.005. Online ahead of print. 1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Federal Region of Kurdistan, Iraq. 2 Cardiovascular Trials Unit, Manchester University...
Implications: PCSK9monoclonal antibodies markedly reduce LDL-C and consistently reduce cardiovascular mortality in patients with and without diabetes. Current evidence does not suggest an adverse effect of PCSK9 monoclonal antibodies on glycemic parameters.
Share
Conclusions: PK regulates circulating cholesterol levels through binding to LDLR and inducing its lysosomal degradation. Ablation of PK stabilizes LDLR, decreases LDL cholesterol, and prevents atherosclerotic plaque development. This study suggests that PK is a promising therapeutic target to treat atherosclerotic cardiovascular disease.
Share
Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35209731/
2022 Feb 25;CIRCINTERVENTIONS121011382. doi: 10.1161/CIRCINTERVENTIONS.121.011382. Online ahead of print. 1 Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (R.H.M.F.). 2 Instituto do Coracao (InCor), Hospital das Clinicas da...
Conclusions: Evolocumab reduces the risk of MACE in patients with prior PCI including the risk of coronary revascularization, with directionally consistent effects across several types of revascularization procedures, including coronary artery bypass grafting and PCI for stent or graft failure.
Share
Trends in PCSK9 Inhibitor Utilization in the United States, Europe and Other Countries: An Analysis of International Sales Data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35240102/
First approved in July 2015, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are costly lipid-lowering drugs. Their utilization has important policy and clinical implications but has not been assessed...
Relevance: First approved in July 2015, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are costly lipid-lowering drugs. Their utilization has important policy and clinical implications but has not been assessed across different geographical regions. The objective of this study was to describe trends in PCSK9 inhibitor adoption...
Share